CLINICAL_TRIALS
trial_result
· 2010-01-07
Clinical Trial Update: IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC) [Phase 1]
Summary
A Phase 1 trial of IMP321 (Immutep S.A.S.) for metastatic renal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Immutep S.A.S. | Conditions: Stage IV Renal Cell Carcinoma | Phase 1 | Status: COMPLETED